Pharmacogenomic Study of Anthracycline-Induced Cardiotoxicity in Mexican Pediatric Patients

References

• Mcgowan JV , ChungR , MaulikA , PiotrowskaI , WalkerJM , YellonDM. Anthracycline chemotherapy and cardiotoxicity. Cardiovasc. Drugs Ther.31(1), 63–75 (2017).
   PubMed Web of Science ®Google Scholar
• Lipshultz SE , AlvarezJA , ScullyRE. Anthracycline associated cardiotoxicity in survivors of childhood cancer. Heart94(4), 525–533 (2008).
   PubMed Web of Science ®Google Scholar
• Smith LA , CorneliusVR , PlummerCJet al. Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials. BMC Cancer10(337), 1–14 (2010).
   PubMedGoogle Scholar
• Bansal N , AmdaniSM , HutchinsKK , LipshultzSE. Cardiovascular disease in survivors of childhood cancer. Curr. Opin. Pediatr.30(5), 628–638 (2018).
   PubMed Web of Science ®Google Scholar
• Van Der Pal HJ , Van DalenEC , HauptmannMet al. Cardiac function in 5-year survivors of childhood cancer: a long-term follow-up study. Arch. Intern. Med.170(14), 1247–1255 (2010).
   PubMedGoogle Scholar
• Kremer LC , VanDer Pal HJ , OffringaM , Van DalenEC , VoutePA. Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review. Ann. Oncol.13(6), 819–829 (2002).
   PubMed Web of Science ®Google Scholar
• Lipshultz SE , LipsitzSR , SallanSEet al. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J. Clin. Oncol.23(12), 2629–2636 (2005).
   PubMed Web of Science ®Google Scholar
• Berthiaume JM , WallaceKB. Adriamycin-induced oxidative mitochondrial cardiotoxicity. Cell Biol. Toxicol.23(1), 15–25 (2007).
   PubMed Web of Science ®Google Scholar
• Henriksen PA . Anthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention. Heart104(12), 971–977 (2018).
   PubMed Web of Science ®Google Scholar
• Zhang S , LiuX , Bawa-KhalfeTet al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat. Med.18(11), 1639–1642 (2012).
   PubMed Web of Science ®Google Scholar
• Zamorano JL , LancellottiP , RodriguezMuñoz Det al. 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the task force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur. Heart J.37(36), 2768–2801 (2016).
   PubMed Web of Science ®Google Scholar
• Barry E , AlvarezJA , ScullyRE , MillerTL , LipshultzSE. Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management. Expert. Opin. Pharmacother.8(8), 1039–1058 (2007).
   PubMed Web of Science ®Google Scholar
• Sapkota Y , QinN , EhrhardtMJ. Genetic variants associated with therapy-related cardiomyopathy among childhood cancer survivors of African ancestry. Cancer Res.81(9), 2556–2565 (2021).
   PubMed Web of Science ®Google Scholar
• Hutchins KK , SiddeekH , FrancoVI , LipshultzSE. Prevention of cardiotoxicity among survivors of childhood cancer. Br. J. Clin. Pharmacol.83(3), 455–465 (2017).
   PubMed Web of Science ®Google Scholar
• Blanco JG , SunCL , LandierWet al. Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes – a report from the Children’s Oncology Group. J. Clin. Oncol.30(13), 1415–1421 (2012).
   PubMed Web of Science ®Google Scholar
• Krajinovic M , ElbaredJ , DrouinSet al. Polymorphisms of ABCC5 and NOS3 genes influence doxorubicin cardiotoxicity in survivors of childhood acute lymphoblastic leukemia. Pharmacogenomics J.16(6), 530–535 (2016).
   PubMed Web of Science ®Google Scholar
• Lipshultz SE , LipsitzSR , KutokJLet al. Impact of hemochromatosis gene mutations on cardiac status in doxorubicin-treated survivors of childhood high-risk leukemia. Cancer119(19), 3555–3562 (2013).
   PubMed Web of Science ®Google Scholar
• Visscher H , RossCJ , RassekhSRet al. Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children. J. Clin. Oncol.30(13), 1422–1428 (2012).
   PubMed Web of Science ®Google Scholar
• Tripaydonis A , ConyersR , ElliottDA. Pediatric anthracycline-induced cardiotoxicity: mechanisms, pharmacogenomics, and pluripotent stem-cell modeling. Clin. Pharmacol. Ther.105(3), 614–624 (2019).
   PubMed Web of Science ®Google Scholar
• Aminkeng F , BhavsarAP , VisscherHet al. A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer. Nat. Genet.47(9), 1079–1084 (2015).
   PubMed Web of Science ®Google Scholar
• Visscher H , RossCJ , RassekhSRet al. Validation of variants in SLC28A3 and UGT1A6 as genetic markers predictive of anthracycline-induced cardiotoxicity in children. Pediatr. Blood Cancer60(8), 1375–1381 (2013).
   PubMed Web of Science ®Google Scholar
• Vargas-Neri JL , Castelan-MartinezOD , DeJesus Estrada-Loza M , Betanzos-CabreraY , Rivas-RuizR. Anthracycline-induced cardiotoxicity: report of fatal cases. Rev. Med. Inst. Mex. Seguro Soc.54(3), 404–408 (2016).
   PubMedGoogle Scholar
• Vargas Neri JL , Castelan-MartinezOD , Castañeda-HernandezGet al. Adverse drug reactions associated with anthracycline-based chemotherapy in Mexican cancer pediatric patients: cohort study. Lat. Am. J. Clin. Sci. Med. Technol.Feb 2, 9–17 (2020).
   Google Scholar
• Cal F , LutsMAF , LinXet al. Anthracycline-induced cardiotoxicity in the chemotherapy treatment of breast cancer: Preventive strategies and treatment. Mol. Clin. Oncol.11(1), 15–23 (2019).
   PubMed Web of Science ®Google Scholar
• Aminkeng F , RossCJ , RassekhSRet al. Recommendations for genetic testing to reduce the incidence of anthracycline-induced cardiotoxicity. Br. J. Clin. Pharmacol.82(3), 683–695 (2016).
   PubMed Web of Science ®Google Scholar
• Gauderman Wj MJ . QUANTO 1.1: a computer program for power and sample size calculations for genetic-epidemiology studies (2006). https://mybiosoftware.com/quanto-1-2-4-computes-sample-size-power-association-studies.html
   Google Scholar
• Linschoten M , TeskeAJ , CramerMJ , VanDer Wall E , AsselbergsFW. Chemotherapy-related cardiac dysfunction: a systematic review of genetic variants modulating individual risk. Circ. Genom. Precis. Med.11(1), e001753 (2018).
   PubMed Web of Science ®Google Scholar
• Innocenti F , IyerL , RamírezJ , GreenMD , RatainMJ. Epirubicin glucuronidation is catalyzed by human UDP-glucuronosyltransferase 2B7. Drug Metab. Dispos.29(5), 686–692 (2001).
   PubMed Web of Science ®Google Scholar
• Krishnaswamy S , HaoQ , Al-RohaimiAet al. UDP glucuronosyltransferase (UGT) 1A6 pharmacogenetics: II. Functional impact of the three most common nonsynonymous UGT1A6 polymorphisms (S7A, T181A, and R184S). J. Pharmacol. Exp. Ther.313(3), 1340–1346 (2005).
   PubMed Web of Science ®Google Scholar
• López M , DoradoP , OrtegaAet al. Interethnic differences in UGT1A4 genetic polymorphisms between Mexican mestizo and Spanish populations. Mol. Biol. Rep.40(4), 3187–3192 (2013).
   PubMed Web of Science ®Google Scholar
• Delacroix L , MoutierE , AltobelliGet al. Cell-specific interaction of retinoic acid receptors with target genes in mouse embryonic fibroblasts and embryonic stem cells. Mol. Cell. Biol.30(1), 231–244 (2010).
   PubMed Web of Science ®Google Scholar
• Rivas-Ruiz R , Ureña-WongK , Castelán-MartínezODet al. Predictors of anthracycline-induced cardiotoxicity in a retro-prolective cohort of children surviving cancer. Gac. Med. Mex.156(3), 217–223 (2020).
   PubMed Web of Science ®Google Scholar